Pioneering strategy to deliver localised chemotherapy for liver cancer
| Reference number | |
| Coordinator | DOUBLE BOND PHARMACEUTICALS AB - Double Bond Pharmaceutical AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | April 2017 - October 2017 |
| Status | Completed |
Important results from the project
The aim of the project was to analyze and evaluate the clinical and market feasibility of SA-033, our innovative drug against liver cancer. During the project, we have also defined all details related to the planned phase 1 clinical validation. The set goals were satisfactorily fulfilled.
Expected long term effects
In the project, we have confirmed the clinical and market feasibility of SA-033 as well as defined all details related to the planned phase 1 clinical validation. The results of our analyzes and assessments will provide a basis for our strategic decisions related to the development of the drug.
Approach and implementation
During the course of the project, we have performed an advanced market analysis including, for instance, the competitive landscape, user needs and regulatory aspects. We have also identified potential partners for the planned out-licensing deal and defined the company´s financial expectations connected to it. In addition, we have developed a plan for the following phase I clinical validation that will be a significant step towards commercialization of the drug.